Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
Views & Analysis Exclusive: Frontiers Health – Day two coverage Frontiers Health is a two-day event focused on disruptive health; innovative technology, application of digital and new ideas which can, are and will transform the face
News Sandoz mhealth hack to address healthcare access Sandoz HACk is encouraging 18-35 year olds to “re-imagine” healthcare.
News Sandoz's Enbrel biosimilar approved in US FDA approves first near-copy of inflammatory diseases drug.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
